Richter Revenue Growth in Line with Expectations

The consolidated revenue of Gedeon Richter Plc. was HUF 224 billion in the first quarter, up 10% year-on-year, the pharmaceutical company announced on the website of the Budapest Stock Exchange (BSE) on Tuesday.

The company posted a profit after tax of HUF 68.1 billion in the first quarter, similar to the previous year.

According to the analyst consensus published by Portfolio.hu, analysts expected sales revenue of HUF 223.9 billion in the first quarter of 2025.

This year, they expect pharmaceutical sales to grow by 10%, with growth accelerating in the second half of the year. The exchange rate, mainly the weaker forint, helped revenues by 4 percentage points in the first quarter, they said.

The report said profits were unchanged from the same period last year, as slightly higher operating profit was offset by lower net financial income and lower contributions from associates. Net financial income increased profit before tax by roughly HUF 13.4 billion.

Pharmaceutical sales increased in all regions, up 6% excluding currency effects to HUF 211.3 billion.

CNS (neuropsychiatry) revenues increased by 13% to nearly HUF 60 billion. The report highlighted that the business was the main driver of growth in adjusted interest income and earnings before tax (EBIT) in the quarter, thanks to continued double-digit growth in Vraylar sales.

Revenues in the women's pharmaceuticals business rose 6.3% to HUF 78.8 billion, with growth slowing due to a high base.

Biotech revenues continued to show double-digit growth, up 14.2% to HUF 13.1 billion, while generics revenues grew 12.1% to HUF 65.5 billion in the quarter.

Reported EBIT increased by 7% to HUF 68.5 billion.

According to the report, Richter confirmed its previous forecast for 2025, which was for growth of around 10% in both revenue and adjusted EBIT, excluding currency effects.